Memphasys Ltd stock analysis
Memphasys Ltd (IG7) Stock Price & Analysis
IG7 Stock Chart & Stats
- Day’s Range
- EUR 0.00 - EUR 0.01
- 52-Week Range
- N/A
- Previous Close
- EUR 0.01
- Volume
- N/A
- Average Volume (3M)
- 3
- Market Cap
- EUR 7.57M
- Enterprise Value
- EUR 23.13M
- Total Cash (Recent Filing)
- EUR 1.18M
- Total Debt (Recent Filing)
- EUR 4.24M
- Price to Earnings (P/E)
- ―
- Beta
- -0.01
- Next Earnings
- Feb 19, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
The strong revenue growth indicates increasing demand for Memphasys's fertility technologies, suggesting successful market penetration and potential for future sales expansion.
Gross Profit Margin
A high gross profit margin reflects efficient production and pricing strategies, which can support long-term profitability as the company scales its operations.
Innovative Product Offering
The innovative Felix device positions Memphasys as a leader in reproductive technology, potentially driving competitive advantage and market share growth in the fertility sector.
Bears Say
Profitability Challenges
Ongoing profitability issues may hinder Memphasys's ability to reinvest in growth and innovation, potentially impacting its long-term financial health and competitive position.
High Debt Levels
High leverage increases financial risk, limiting flexibility and potentially impacting the company's ability to finance future growth or weather economic downturns.
Cash Flow Challenges
Negative cash flows indicate operational inefficiencies and may constrain the company's ability to fund operations, invest in new projects, or manage debt obligations effectively.
Memphasys Ltd News
IG7 FAQ
What is Memphasys Ltd’s market cap?
When is Memphasys Ltd’s upcoming earnings report date?
How were Memphasys Ltd’s earnings last quarter?
Is Memphasys Ltd overvalued?
Does Memphasys Ltd pay dividends?
What is Memphasys Ltd’s EPS estimate?
How many shares outstanding does Memphasys Ltd have?
What happened to Memphasys Ltd’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Memphasys Ltd?
What is the TipRanks Smart Score and how is it calculated?
Memphasys Ltd Stock Smart Score
Company Description
Memphasys Ltd
Memphasys Limited, an Australian enterprise, is dedicated to the development, manufacturing, and distribution of advanced cell and protein separation technologies, alongside associated consumable goods, for the healthcare, veterinary, and biotechnology sectors. Its leading innovation is Felix, an automated device engineered to swiftly and gently isolate high-quality sperm from raw semen samples, primarily for use in human in vitro fertilization (IVF) procedures. The company's product portfolio also includes ROSA, a rapid oxidative stress assay; the Samson Device, designed for quick equine pregnancy prediction; SemPort, a system for central laboratory human semen analysis from geographically dispersed donors; and AI-Port, an ambient temperature semen transport solution for animal artificial insemination. Incorporated in 2006, the company was formerly known as NuSep Holdings Limited until its rebranding to Memphasys Limited in July 2016, and is headquartered in Homebush, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- R. John Aitken
- Employees
- 24
- Website
- www.memphasys.com
- Address
- 30 Richmond Road, Homebush, NSW, 2140, AU











